Have you ever thought about how wonderful it would be if only our immune system could fight and beat cancer cells? As magic as this may sound, this is indeed the job of a bispecific antibody! 

Teclisimab is a subcutaneous injection that redirects T-cells through two cellular targets to activate the body’s immune system to fight cancer (Janssen explains). This week we would like to share a clinical trial related to this drug and address patients with High-Risk Smoldering Myeloma (HRSM).

The Phase II is comparing the anti-cancer activity of teclisimab vs. lenalidomide (Revlimid) + dexamethasone in HRSM.

The patients enrolled will be separated into two different groups. Both will receive treatment in a 28-day cycle. One group will be treated with lenalidomide + dexamethasone, and the other group will be treated with teclisimab as a single agent.

The study is looking a the percentage of patients who achieve a complete response (CR), meaning there is no longer a measurable protein and less than 5% of plasma cells in the bone marrow. The study was also looking at progression-free survival, duration of response and any treatment side effects. 

Patients can joing the study if the have high risk smoldering myeloma (by 2/20/20 criteria.)

Being diagnosed with a precursor condition such as Smoldering Myeloma (SM) can be frustrating and challenging. Still, there are a few things that will help you ease your mind: learning and understanding the basics of your current disease, having a Myeloma specialist, and keeping up to date with all the latest publications and available clinical trials to accelerate research and drive to a cure! 

You can learn more about this clinical trial here:

High-Risk SMM immuno-PRISM Trial